INTRODUCTION {#S1}
============

A delicate balance between quiescence and homeostatic proliferation maintains the T cell pool. An emerging paradigm suggests that quiescence is an actively regulated state, rather than the default state, in the absence of proliferation-inducing signals [@R1]. Homeostatic proliferation of CD8^+^ T cells is an efficient mechanism to maintain the T cell pool during aging [@R2]. However, neither the molecular mechanisms regulating CD8^+^ T cell homeostasis nor its impact on T cell activation and homing are completely understood. The identification of new negative regulators of T cell proliferation is vital to further understand lymphocyte homeostasis and immune responses, as well as to develop protocols of gene modulation to enhance the immunological memory generated after vaccination.

The transcription factor ELF4 (also known as MEF) is a member of the ETS family of proteins [@R3]--[@R5]. Recent reports suggest that ELF4 can function as a tumor suppressor in hematopoietic cells. ELF4 expression is downregulated in acute myelogenous leukemia, either by oncoproteins or by chromosome translocation with the *ERG* gene [@R6]--[@R8]. Using ELF4-deficient mice, we previously demonstrated that ELF4 induces a state of readiness in natural killer (NK) cells by activating perforin gene expression [@R3], [@R9]. We also demonstrated that ELF4 controls the balance between activation and quiescence in hematopoietic stem cells (HSCs) during steady state conditions but not during regenerative hematopoiesis [@R10]. Therefore, we hypothesized that ELF4 may regulate T cell entry into the cell cycle by activating an inhibitor of proliferation.

The Krüppel-like factor 4 (KLF4) is a zinc-finger transcriptional regulator that acts as a tumor suppressor and oncogene in the gastrointestinal tract and breast tissue, respectively [@R11]--[@R13]. In the hematopoietic system, Klf4 gene was found silenced in patients with adult T cell leukemia [@R14]. The recent finding that KLF4 can reprogram adult somatic cells into pluripotent stem cells in combination with Sox2, Oct3/4 and c-Myc suggests a role for this transcription factor in the prevention of cellular proliferation and differentiation [@R15]--[@R17].

KLF2 (<http://www.signaling-gateway.org/molecule/query?afcsid=A004085>) was the first transcription factor described as capable of programming T cell quiescence by inhibiting the c-Myc pathway [@R18]. Other cell-intrinsic inhibitors of T cell proliferation include the FOXO transcription factors, the Tob anti-proliferative protein, dipeptidyl peptidase 2 (Dpp2), and the transcription factor Nfat2c [@R19]--[@R22]. Gene products involved in controlling the cell cycle can also influence the number of antigen-experienced memory CD8^+^ T cells generated at the end of an immune response [@R23]--[@R26]. In addition, the transcription factor T-bet promotes the differentiation of effector T cells over memory precursor cells, whereas the basic helix loop helix protein Id2 regulates the survival of effector T cells via the proteinase inhibitor 6 (Spi6) [@R27]--[@R29].

Memory-like T cells are generated during lymphopenia- or cytokine-induced homeostatic proliferation of naïve T cells[@R2], [@R30]. A similar gene expression profile and the same cell of origin suggests that antigen-experienced and memory-like T cells use common mechanisms to control proliferation [@R31]. Gene products that influence T cell proliferation can also regulate homing receptors and thereby direct T cell trafficking. In contrast to CD62L^lo^CCR7^−^ effector memory T cells (T~em~) that home to non-lymphoid tissues and the spleen, CD62L^hi^CCR7^+^ central memory T cells (T~cm~) home to the lymph nodes (LN) [@R32], [@R33]. KLF2 promotes the circulation of naïve T cells through lymphoid organs by regulating the expression of CD62L, sphingosine 1 phosphate 1 receptor, CCR7, and β~7~-integrin [@R34], [@R35]. Conversely, the suppression of KLF2 expression induced by T cell receptor (TCR) stimulation results in the mobilization of effector T cells to inflamed tissues because KLF2 represses CCR3 and CCR5 expression [@R36]. Although the role of KLF2 has been established in naïve T cells, it has not been defined in memory T cells or in the maintenance of the size of the T cell pool. Neither the transcriptional mechanisms controlling the homeostatic and antigen-driven proliferation of naïve T cells and the differentiation of naïve T cells into memory T cells, nor the lineage relationship between memory T cell subsets have been identified, in spite of the importance of these mechanisms in vaccination and immune protection.

Here we demonstrated that ELF4 regulates the proliferation of naïve CD8^+^ T cells and the tissue distribution of CD8^+^CD44^hi^ T cells. ELF4 activated KLF4 downstream of TCR signaling to induce cell cycle arrest in naïve CD8^+^ T cells. Naïve CD8^+^ T cells from mice lacking ELF4 or KLF4 were 'primed' to proliferate during homeostasis or after immunization, due to accumulation of cyclin D in the cytosol and repression of cyclin-dependent kinase inhibitors. In addition, in ELF4-deficient mice, CD8^+^CD44^hi^ T cell populations gradually accumulated and redistributed to non-lymphoid tissues due to reduced expression of KLF2, CCR7 and CD62L. In addition to KLF2, ELF4 and KLF4 tumor suppressors regulate T cell proliferation and homing.

RESULTS {#S2}
=======

ELF4 suppresses homeostatic and antigen-driven proliferation {#S3}
------------------------------------------------------------

To test whether ELF4 regulates cell cycle entry in naïve CD8^+^ T cells similarly to HSC, we measured proliferation in response to homeostatic and antigen-driven stimuli. We used two systems to test homeostatic proliferation of *Elf4*^−/−^ CD8^+^ T cells: *in vivo* BrdU incorporation and adoptive transfer of naïve CD8^+^ T cells into lymphopenic hosts. Although administration of BrdU revealed a low rate of T cell proliferation, activated *Elf4*^−/−^ CD8^+^CD44^hi^ T cells incorporated significantly more BrdU than did *Elf4*^+/+^ CD8^+^CD44^hi^ T cells ([Fig. 1a](#F1){ref-type="fig"}). Next, CD8^+^ CD44^lo^CD45.2^+^ T cells were purified from *Elf4*^+/+^ and *Elf4*^−/−^ mice, labeled with CFSE and adoptively transferred into sublethally irradiated B6.SJL mice to induce homeostatic proliferation. At least 80% of the transferred *Elf4*^−/−^ CD8^+^ T cells underwent more than 5 divisions compared to only 17% of the *Elf4*^+/+^ CD8^+^ T cells ([Fig. 1b](#F1){ref-type="fig"}). Furthermore, the *Elf4*^−/−^ naïve CD8^+^ T cells out-competed the *Elf4*^+/+^ CD8^+^ T cells when the two populations were co-injected into irradiated B6.SJL mice ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} online). To determine whether self-renewal of memory-like T cells is also increased, we purified CD8^+^CD44^lo^ and CD8^+^CD44^hi^ T cells and measured their proliferation *in vitro*. IL-15 induced similar proliferation of *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^CD44^hi^ T cells ([Fig. 1c](#F1){ref-type="fig"}). In contrast, CD8^+^CD44^lo^ T cells isolated from *Elf4*^−/−^ mice proliferated more than *Elf4*^+/+^ CD8^+^CD44^lo^ cells in response to TCR activation ([Fig. 1c](#F1){ref-type="fig"}). Similar results were observed when adoptively transferred *Elf4*^+/+^ OT-1 CD8^+^CD44^lo^ T cells or *Elf4*^−/−^ OT-1 CD8^+^CD44^lo^ CD8^+^ T cells were activated *in vivo* by intravenous administration of OVA~257--264~ peptide ([Fig. 1d](#F1){ref-type="fig"}). This readiness to proliferate suggests a lower threshold of activation. In support of this hypothesis, *Elf4*^−/−^ OT-1 CD8^+^ T cells underwent more proliferation than *Elf4*^+/+^ OT-1 CD8^+^ T cells in response to low concentrations of OVA~257--264~ peptide *in vitro* ([Fig. 1e](#F1){ref-type="fig"}).

Aberrant expression of factors that facilitate the G~1~- to S-phase transition can prime T cells to rapidly proliferate upon activation. TCR crosslinking induced faster phosphorylation of Rb in *Elf4*^−/−^ CD8^+^ T cells than *Elf4*^+/+^ CD8^+^ T cells ([Fig. 1f](#F1){ref-type="fig"}). Additionally, the expression of cyclins D1, D3 and E was increased, whereas the expression of the p21, p15 and p27 cell cycle inhibitors was reduced in *Elf4*^−/−^ compared to *Elf4*^+/+^ CD8^+^ T cells ([Fig. 1g](#F1){ref-type="fig"}). This finding, together with the accumulation of cyclins D1 and D3 in the cytosol of *Elf4*^−/−^ CD8^+^ T cells, is consistent with the notion that *Elf4*^−/−^ CD8^+^ T cells exist in a late G1 stage ([Fig. 1h](#F1){ref-type="fig"}). Although we did not detect a substantial amount of phosphorylated Rb in unstimulated *Elf4*^−/−^ CD8^+^ T cells, the BrdU incorporation experiments suggested a higher steady-state proliferation rate of this population ([Fig. 1a](#F1){ref-type="fig"}). Collectively, we propose that the transcription factor ELF4 negatively regulates proliferation of naïve CD8^+^ T cells by raising the activation threshold. Thus, we investigated the effect of *Elf4* deletion on the generation of memory-like and antigen-experienced memory T cells during homeostasis and antigen driven presentation, respectively.

ELF4 regulates naïve T cell quiescence {#S4}
--------------------------------------

Homeostatic proliferation of naïve T cells contributes to the maintenance of the T cell pool, especially as thymic production wanes during aging, leading to accumulation of T cells with a memory-like phenotype [@R30], [@R37], [@R38]. These memory-like CD8^+^CD44^hi^CD122^+^ T cells are detected even in mice kept in a pathogen-free environment. The percentage of CD44^hi^CD122^+^ cells within the CD8^+^ T cell pool gradually increases with age to constitute 30--40% of CD8^+^ T cells in the spleens of wild-type mice ([Fig. 2a](#F2){ref-type="fig"}). The expansion of the CD8^+^CD44^hi^CD122^+^ T cell population was significantly accelerated in *Elf4*^−/−^ mice, such that up to 70% of the total CD8^+^ T cell compartment in 13-month-old mice was CD44^hi^CD122^+^ ([Fig. 2a](#F2){ref-type="fig"}). This accumulation correlated with a reduction in the number of naïve CD8^+^CD44^lo^ T cells, suggesting that CD8^+^ T cells in *Elf4*^−/−^ mice are spontaneously activated. In addition, *Elf4*^−/−^ mice displayed splenomegaly and hyperplasia of the white pulp, accumulation of CD4^+^ and CD8^+^ T cells in the spleen, and lymphocytic infiltration of the liver, with age ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"} online). To determine whether this T cell population expansion was due to T cell-intrinsic factors, we generated bone marrow (BM) chimeras using GFP^+^ *Elf4*^+/+^ or GFP^+^ *Elf4*^−/−^ BM cells as donors and wild-type mice as recipients. The percentage of CD44^hi^CD122^+^ cells in the CD8^+^ T cell pool derived from *Elf4*^−/−^ donor cells increased over time at a rate significantly greater than that of *Elf4*^+/+^ donor-derived cells, suggesting that the accelerated expansion of *Elf4*^−/−^ T cell populations is T cell intrinsic and not due to an altered environment in *Elf4*^−/−^ mice ([Fig. 2b](#F2){ref-type="fig"}).

Outgrowth of autoreactive T cell clones could potentially account for the T cell population expansion observed in *Elf4*^−/−^ mice. However, we noted a similar distribution of TCR V~β~chains on CD8^+^CD44^hi^ T cells in *Elf4*^−/−^ mice compared to age-matched *Elf4*^+/+^ controls, suggesting that the T cell population was polyclonal rather than oligoclonal ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"} online). We also examined the homeostatic expansion of *Elf4*^−/−^ T cell populations specific for a foreign antigen by crossing *Elf4*^−/−^ mice to OT-1 transgenic mice. OT-1 *Elf4*^−/−^ mice accumulated CD8^+^CD44^hi^CD122^+^ T cells at a rate and to an extent similar to *Elf4*^−/−^ mice ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"} online). In addition, whereas the majority (77%) of CD8^+^CD44^hi^ CD122^+^ T cells in OT-1 *Elf4*^−/−^ mice stained with the H2-K^b^-OVA~257--264~ tetramer, only 16% of CD8^+^CD44^hi^CD122^+^ T cells in OT-1 *Elf4*^+/+^ mice bound this tetramer. Therefore, ELF4 regulates T cell homeostasis, and *Elf4*^−/−^ mice exhibit polyclonal T cell population expansion due to T cell-intrinsic defect(s).

ELF4 regulates the expression of KLF2 {#S5}
-------------------------------------

Next we analyzed T cell distribution in different tissues of aged *Elf4*^+/+^ and *Elf4*^−/−^ mice because a continuously expanding T cell pool could induce a redistribution of T cells. In 13-month-old *Elf4*^−/−^ mice, CD8^+^CD44^hi^ T cells accumulated in the spleen, blood, liver, lung, and BM but not in the LNs ([Fig. 3a](#F3){ref-type="fig"}). Even though there was no accumulation of cells in the LNs, the presence of some *Elf4*^−/−^ memory-like T cells in this tissue could be due to entry via afferent lymphatics. Next, we examined the cell surface expression of CD62L---an indicator of LN homing potential---on *Elf4*^−/−^ CD8^+^ T cells ([Fig. 3b](#F3){ref-type="fig"}). Although CD8^+^CD44^lo^ T cells demonstrated similar CD62L expression in 3-month and 13-month-old *Elf4*^+/+^ and *Elf4*^−/−^ mice, the expression of CD62L was substantially downregulated on CD8^+^CD44^hi^ T cells from 13-month-old *Elf4*^−/−^ mice ([Fig. 3b](#F3){ref-type="fig"}). This downregulation of CD62L was a gradual process that correlated with T cell expansion ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"} online). CCR7 was also downregulated in CD8^+^CD44^hi^ T cells from 13-month-old *Elf4*^−/−^ mice ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"} online). Expansion of CD44^hi^ T cells in *Elf4*^−/−^ is not exclusive of CD8^+^ T cells, CD4^+^CD44^hi^ T cells also accumulated and lost CD62L and CCR7 expression over time ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"} online). Loss of CD62L and CCR7 expression on CD8^+^CD44^hi^ T cells suggests an age-dependent conversion of T~cm~ to T~em~ phenotype. To evaluate the relationship between these subsets, we tracked the cell fate of adoptively transferred memory T cell populations from *Elf4*^+/+^ and *Elf4*^−/−^ mice. T~em~ cells purified from *Elf4*^+/+^ and *Elf4*^−/−^ mice did not significantly acquire CD62L expression upon adoptive transfer ([Fig. 3c](#F3){ref-type="fig"}). However, unlike *Elf4*^+/+^ T~cm~ cells, approximately 80% of the *Elf4*^−/−^ T~cm~ cells lost CD62L from the cell surface by 35 days after adoptive transfer ([Fig. 3c](#F3){ref-type="fig"}).

Homeostatic expansion of CD8^+^ T cell populations in *Elf4*^−/−^ mice leads to the continuous accumulation of CD8^+^CD44^hi^CD62L^lo^ T cells, suggesting that ELF4 may be regulating the expression of inducers of CD62L expression. Hence, we examined expression of KLF2---the main activator of CD62L expression in naïve T cells---in *Elf4*^−/−^ CD8^+^ T cells [@R34], [@R35]. CD62L and KLF2 mRNA and protein expression was reduced in CD8^+^ T cells isolated from 13-month-old *Elf4*^−/−^ mice ([Fig. 4a](#F4){ref-type="fig"}). To confirm that this effect was due to ELF4, *Elf4*^−/−^ mice were crossed to Vav-ELF4 transgenic mice to restore ELF4 activity in the hematopoietic system. As predicted, the ectopic expression of ELF4 restored CD62L expression on the surface of CD8^+^CD44^hi^ T cells of 13-month-old *Elf4*^−/−^ mice ([Fig. 4b](#F4){ref-type="fig"}). Reduced CD62L mRNA was observed in CD8^+^CD44^hi^ T cells from 13-month-old *Elf4*^−/−^ mice, and this reduction was prevented by transgenic expression of ELF4 ([Fig. 4c](#F4){ref-type="fig"}). Even though ELF4 can activate the *Klf2* promoter *in vitro* ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"} online), we were unable to detect ELF4 bound to the *Klf2* regulatory sequences in CD8^+^ T cells isolated from *Elf4*^+/+^ 13-month-old mice ([Fig. 4d](#F4){ref-type="fig"}). However, the chromatin immunoprecipitation analyses demonstrated that KLF2, but not ELF4, bound to the *Sell* promoter in *Elf4*^+/+^ but not *Elf4*^−/−^ CD8^+^ T cells ([Fig. 4d](#F4){ref-type="fig"}). Of note, normal levels of Foxo1, another activator of CD62L and CCR7 expression in naïve T cells [@R39], were found in *Elf4*^−/−^ CD8^+^CD44^hi^ T cells (data not shown). Collectively, this suggests that the homeostatic expansion of CD8^+^ T cell populations with a memory-like phenotype results in downregulation of CD62L and CCR7, which diverts the excess CD8^+^CD44^hi^ T cells from the LNs to the spleen and non-lymphoid tissues.

ELF4 restricts memory after vaccination {#S6}
---------------------------------------

Cell cycle regulation plays a critical role in the clonal expansion of antigen-specific naïve T cell populations during infection or vaccination. To test whether ELF4 also regulates proliferation upon priming, we used dendritic cells (DC) pulsed with OVA~257--264~ peptide (DC-OVA) to immunize B6.SJL mice that had been adoptively transferred 24 hours earlier with CD8^+^ T cells isolated from either OVA-specific OT-1 *Elf4*^+/+^ or OT-1 *Elf4*^−/−^ mice. H-2K^b^-OVA tetramer staining demonstrated a significantly higher proportion and number of *Elf4*^−/−^ compared to *Elf4*^+/+^ OVA-specific CD8^+^ T cells at the peak of expansion (day 4) and at day 40 ([Fig. 5a](#F5){ref-type="fig"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"} online). To rule out microenvironmental effects, we transferred a 1:1 mixture of *Elf4*^+/+^ and *Elf4*^−/−^ OT-1 CD8^+^ T cells into B6.SJL recipients. *Elf4*^+/+^ CD8^+^ T cells were outcompeted by *Elf4*^−/−^ CD8^+^ T cells following immunization in the same environment ([Fig. 5b](#F5){ref-type="fig"}).

Our data suggest that the naïve *Elf4*^−/−^ CD8^+^ T cell populations did not exhaust the memory precursor cells (MPEC) during differentiation to effector T cells. Even though the distribution of short-lived effector (SLEC) and MPEC did not differ significantly between *Elf4*^+/+^ and *Elf4*^−/−^ donor-derived CD8^+^ T cells, the overall expansion of both subsets was greater for *Elf4*^−/−^ CD8^+^ T cells ([Fig. 5c](#F5){ref-type="fig"}). A caveat to this determination is that not all MPEC identified in this way become memory T cells following DC vaccination [@R40], [@R41]. Despite this limitation, our MPEC accumulation findings correlated with the increased number of tetramer positive CD8^+^ T cells detected at late time points after vaccination. We next performed *in vivo* cytolytic assays to evaluate whether *Elf4*^−/−^ memory CD8^+^ T cells generated after vaccination can recognize and lyse antigen-bearing target cells (CFSE^bright^ OVA-pulsed splenocytes). Compared to the OVA-specific memory CD8^+^ T cells generated from *Elf4*^+/+^ OT-1 cells, those generated from *Elf4*^−/−^ OT-1 CD8^+^ T cells more efficiently lysed antigen-bearing target cells *in vivo* ([Fig. 5d](#F5){ref-type="fig"}). However, this assay was not analyzed on a cell-to-cell basis; thus the apparent higher specific lysis by *Elf4*^−/−^ memory T cells was due to their increased frequency in the spleen. Therefore, our data indicate that ELF4 negatively regulates the clonal proliferation of naïve CD8^+^ T cells and the generation of functional memory T cells after immunization.

KLF4 inhibits proliferation of CD8^+^ T cells {#S7}
---------------------------------------------

We hypothesized that ELF4 most likely activates the expression of an inhibitor of proliferation, because ELF4 does not have a known direct role in the progression of the cell cycle. In an effort to identify ELF4 target genes, we performed global gene expression analysis using RNA isolated from resting and in vitro activated CD8^+^ T cells. Most of the differences *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells were detected in the non-activated populations ([Fig. 6a](#F6){ref-type="fig"}). Naïve *Elf4*^−/−^ CD8^+^ T cells expressed higher amounts of factors that promote passage through the G1-to -S-phase transition and lower amounts of factors that inhibit cell cycle progression ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"} online). In addition, the expression of KLF4 was significantly downregulated in *Elf4*^−/−^ CD8^+^ T cells. We decided to further investigate KLF4 given its homology to KLF2 and its dual function as tumor suppressor and oncogene [@R11], [@R42].

If ELF4 negatively regulates T cell proliferation by directly inducing expression of KLF4, this ELF4-mediated suppression of proliferation must be blocked during T cell activation. In agreement with this hypothesis, the expression of ELF4 and KLF2 decreased immediately after TCR activation, whereas expression of KLF4 decreased 16--20 hours later ([Fig. 6b](#F6){ref-type="fig"}). In further support of this model, the expression of KLF4 and p21 inversely correlated with the extent of proliferation of CD8^+^ T cells from *Elf4*^−/−^ and *Elf4*^−/−^ Vav-ELF4 mice ([Fig. 7a](#F7){ref-type="fig"}). Ectopic expression of ELF4 restored the expression of KLF4 and p21 and normalized the proliferation of *Elf4*^−/−^ CD8^+^ T cells by increasing the percentage of non-proliferative T cells ([Fig.7b](#F7){ref-type="fig"}). This finding suggests that the hyperproliferation of *Elf4*^−/−^ CD8^+^ T cells is due to defective expression of KLF4 and p21 ([Fig. 7a](#F7){ref-type="fig"}). Reporter assays demonstrated that *Klf4* transcription is induced by ELF4, as well as by the known activator SP1 ([Fig. 7c](#F7){ref-type="fig"})[@R43]. To further confirm the direct regulation of *Klf4* by ELF4 *in vivo*, we performed ChIP assays to evaluate *Klf4* promoter occupancy. We detected *Klf4* regulatory sequences by PCR using primers that span the *Klf4* promoter among the DNA immunoprecipitated with anti-ELF4 ([Fig. 7d](#F7){ref-type="fig"}). These data indicate that KLF4 maintains T cell quiescence downstream of ELF4, perhaps by directly activating p21 expression in CD8^+^ T cells.

To directly assess the influence of KLF4 on T cell proliferation, we generated ^Klf4^-deficient mice to test the effect of KLF4 in T cell proliferation. We crossed *Klf4*-floxed mice (*Klf4*^fl/fl^) to Mx1-Cre (Cre) transgenic mice to induce deletion of the *Klf4* gene in adult mice with polyI:C. The efficacy of *Klf4* gene deletion was confirmed by PCR using genomic DNA isolated from purified CD8^+^ T cells ([Fig. 7e](#F7){ref-type="fig"}). *Klf4*^fl/+^ Mx1-Cre^+^ mice were not used as controls because Elf4 heterozygosis leads to expansion of CD8^+^CD44^hi^CD122^+^ T cells ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"} online). The effect of transient Cre expression on T cell expansion was indirectly evaluated using CD8^+^ T cells from CD4-Cre transgenic mice ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"} online). *In vitro* TCR cross-linking experiments demonstrated that CD8^+^ T cells from *Klf4*^Δ/Δ^ mice proliferated more than the *Klf4*^fl/fl^ controls ([Fig. 7e](#F7){ref-type="fig"}). Furthermore, *Klf4*-deficient mice exhibited increased homeostatic expansion of CD8^+^CD44^+^ T cells in the spleen, similar to that observed in aged *Elf4*^−/−^ mice ([Fig. 7f](#F7){ref-type="fig"}). Our data collectively indicate that circulating CD8^+^ T cells remain quiescent due to the coordinated expression of ELF4 and KLF4, and that TCR activation disrupts this inhibition of proliferation by repressing ELF4 expression.

DISCUSSION {#S8}
==========

Here we demonstrated that ELF4 controls homeostatic and antigen-driven T cell proliferation and T cell homing by inducing expression of KLF4 and KLF2, respectively. ELF4 transactivates the tumor suppressor *Klf4* in naïve CD8^+^ T cells, which is needed to maintain the quiescent state. Loss of ELF4 leads to deregulated T cell population expansion during homeostasis and after immunization, likely due to enrichment of factors that promoting progression through the G1-to S-phase transition. Similarly, deletion of ^Klf4^ results in increased homeostatic expansion of CD8^+^CD44^hi^ T cell populations and deregulated proliferation of CD8^+^CD44^lo^ T cells upon activation. This inhibition of proliferation is disrupted upon T cell activation by inhibition of the *Elf4* and *Klf4* genes. In addition, we observed a progressive shift in the tissue distribution of CD8^+^CD44^hi^ T cells due to loss of KLF2, CCR7 and CD62L expression; KLF2-deficient cells homed to non-lymphoid tissues, presumably in order to accommodate a growing pool of memory-like T cells.

This work suggests that the tumor suppressor KLF4 is a negative regulator of naïve CD8^+^ T cell proliferation downstream of ELF4. These intrinsic regulatory factors not only prevent homeostatic proliferation in response to weak self-MHC signals but also prevent clonal expansion of naïve CD8^+^ T cells and the generation of immunological memory. Adoptive transfer experiments demonstrated that ELF4-dependent homeostatic expansion of CD8^+^ T cells is independent of environmental factors, some of which (e.g. IL-7 and IL-15) are important extrinsic regulators of homeostatic T cell proliferation [@R2]. The enhanced antigen-driven proliferation of *Elf4*^−/−^ CD8^+^ T cells is also cell autonomous, as immunization of recipients of both *Elf4*^−/−^ and *Elf4*^+/+^ OT-1 CD8^+^ T cells resulted in *Elf4*^−/−^ OT-1 CD8^+^ T cells out-competing *Elf4*^+/+^ OT-1 CD8^+^ T cells in the same environment.

In addition to CD4^+^ and CD8^+^ T cells, ELF4 regulates proliferation of B cells [@R9], ovarian epithelial cancer cell lines [@R44], and HSCs [@R10]. ELF4 and c-Myb are the only known negative regulators of HSC quiescence during homeostasis [@R10], [@R45]. In contrast to HSCs, *Elf4*^−/−^ naïve T cells remain in the late-G1 stage poised to proliferate. We demonstrated that the tumor suppressor *Klf4* is directly regulated by ELF4, and that KLF4 expression correlates with expression of the p21 cell cycle inhibitor in naïve T cells. Interestingly, the 'pre-activated' state of *Elf4*^−/−^ CD8^+^ T cells is reminiscent of memory T cells [@R46]. There are no previous reports describing a role for KLF4 in T cell proliferation, although *Klf4* has been shown to suppress B cell proliferation as a target of the FOXO transcription factor [@R47].

Recent reports have identified cell surface molecules that are required for trafficking of naïve T cells to the LNs and inflamed tissues [@R34], [@R35], [@R36], [@R48]. Even though KLF2 is the best-known trafficking 'controller' in naïve T cells, the role of KLF2 in tissue homing and the relationship among different subsets of memory T cells was unknown. Deletion of *Elf4* led to the loss of KLF2, CCR7 and CD62L expression in CD8^+^CD44^hi^ T cells. We demonstrated that even though KLF2 regulates CD62L in CD8^+^ T cells, ELF4 does not activate KLF2 expression in spite of its ability to activate the *Klf2* promoter *in vitro*. Genes activated by ETS proteins *in vitro* often do not correlate with their role *in vivo* due to cell specific transcriptional machinery and functional redundancy. Therefore, the increased homeostatic proliferation of CD8^+^ T cells triggers downregulation of KLF2 and accumulation of CD8^+^CD44^hi^CD62L^lo^ T cells, presumably in order to prevent LN swelling. In fact, it was recently shown that exacerbated expansion of memory CD8^+^ T cell populations results in an increase in the numbers of CD8^+^CD44^hi^CD62L^lo^ T cells in the spleen and non-lymphoid tissues but not in the LNs [@R49]. Interestingly, loss of CD62L expression has been detected in T lymphocytes from elderly humans, and therefore *Elf4* deletion may accelerate the normal process of aging in the immune system [@R50]. The signals that regulate the size of the CD8^+^ T cell pool in the LNs are largely unknown, although data obtained in the present study support the argument that ELF4 prevents CD8^+^ T cells from reaching the size limit of the T cell pool. Our findings also support the hypothesis that the size of the CD8^+^ T cell pool is flexible rather than invariable as was previously thought [@R49]. Our findings also raise the question of whether ELF4 regulates the relationship between T~cm~ and T~em~ cells, and the retention of T~cm~ cells in the LNs. However, it is possible that this apparent conversion of T~cm~ into T~em~ cells actually represents T~cm~ cells that have lost CD62L and CCR7 expression but have retained all other features of T~cm~ cells.

In summary, our study identified two important functions of the transcription factor ELF4. First, ELF4 acts as a negative regulator of naïve CD8^+^ T cell proliferation by directly activating expression of *Klf4*. Second, by inducing expression of KLF2, ELF4 maintains CD62L and CCR7 expression on memory T cells. In this way, ELF4 regulates proliferation in naïve T cells and homing to the LN in memory T cells. A detailed map of the transcriptional machinery involved in the generation of antigen-specific memory CD8^+^ T cells is needed to improve long-lasting immune protection. Hence, modulation of ELF4 or KLF4 expression could be used in the future to heighten immune response and immunological memory by augmenting the clonal expansion of antigen-specific cells without promoting their terminal differentiation into effector T cells.

METHODS {#S9}
=======

Mice {#S10}
----

*Elf4*^−/−^ and Vav-ELF4 mice were obtained from S. Nimer (Memorial Sloan-Kettering Cancer Center, New York) (backcrossed for more than 12 generations to C57BL/6 background). *Klf4*^fl/+^ mice were obtained from K. Kaestner (University of Pennsylvania, Philadelphia) [@R51]. C57BL/6 (B6), B6.SJL, OT-1 TCR transgenic and GFP transgenic mice were purchased from Jackson Laboratories. *Klf4*^fl/fl^ mice were crossed with Mx1-Cre transgenic mice (Jackson Laboratories) to induce deletion. The OT-1 and GFP transgenic mice were crossed with *Elf4*^−/−^ mice to generate OT-1 *Elf4*^−/−^ and GFP^+^ *Elf4*^−/−^ mice. For adoptive transfers, B6 mice were crossed with B6.SJL mice to generate *Elf4*^+/+^ CD45.1^+^ CD45.2^+^ mice. Mice were irradiated using a Gammacell 40 Exactor (Nordion) irradiator for BM transplantation (9.5 Gy) or to induce lymphopenia (4.5 Gy). All mice were bred and maintained under specific pathogen-free conditions at the Baylor College of Medicine. All experiments were performed with the approval of the Institutional Animal Care and Usage Committee of Baylor College of Medicine.

Flow cytometry {#S11}
--------------

The following fluorescence- or biotin-labeled antibodies were used: anti-CD44-phycoerythrin (PE) (IM7), anti-CD45.1-PE (A20), anti-CD45.2-FITC (104), anti-CD122-FITC (TM-β1), anti-CD8-APC (53-6.7), anti-KLRG1-biotin (2F1), anti-CD127-PE (SB/199) and anti-CD62L-APC (MEL-14). All antibodies and streptavidin-APC used in this study were purchased from BD Biosciences. CCL19-Fc and PE-labeled anti-human IgG Fcγ fragment were used for CCR7 staining (eBioscience). TCR V~β~ repertoire was analyzed using a panel of mouse TCR V~β~ chain-specific antibodies (BD Biosciences). PE-labeled H2-K^b^-OVA~257--\ 264~ tetramer was obtained from the MHC Tetramer Core Laboratory (Baylor College of Medicine). Samples were analyzed by flow cytometry using a FACSCanto instrument (BD Biosciences) and FlowJo software (Tree Star). CFSE dilution was analyzed using ModFit software (Verity).

Purification of CD8^+^ T cells {#S12}
------------------------------

CD8^+^ T cells were purified from spleen using the negative selection BD-IMag magnetic-bead separation system (BD Biosciences) following the manufacturer's instructions. Purified CD8^+^ T cells were stained with PE-labeled anti-CD44 to purify CD8^+^CD44^hi^ (memory-like) and CD8^+^CD44^lo^ (naïve) T cells using a MoFlo cell sorter (Cytomation Inc.).

Adoptive transfer {#S13}
-----------------

CD8^+^CD44^hi^CD62L^+^ and CD8^+^CD44^hi^CD62L^−^ T cells were purified by cell sorting from CD45.2^+^ mice. Purified cells (1 × 10^4^) were adoptively transferred into non-irradiated B6.SJL mice (CD45.1^+^). Cell fate was analyzed 35 days later based on the expression of CD62L in donor-derived T cells (CD45.2^+^).

T cell proliferation {#S14}
--------------------

CD8^+^ T cells isolated from spleen were labeled with 4 µM of carboxyfluorescein diacetate succinimidyl ester (CFSE, Invitrogen) in PBS with 0.1% BSA at 37°C for 10 min. CFSE was removed by washing cells with ice-cold RPMI containing 10% fetal bovine serum. For *in vitro* stimulation, CD8^+^CD44^lo^ T cells were isolated from 3-month-old mice, labeled with CFSE and cultured in anti-CD3 coated 96-well plates (Bio-Coat, BD Biosciences) in the presence of 2 µg/ml of anti-CD28 (BD Biosciences) at 1 × 10^5^ cells/well in RPMI containing 10% FBS and 5% T-Stim (BD Biosciences). CD8^+^CD44^hi^ T cells were stimulated with rmIL-15 (20 ng/ml) (R&D Systems) for 7 days. For *in vivo* stimulation, 5 × 10^6^ CFSE-labeled CD8^+^ T cells from 3-month-old OT-1 *Elf4*^+/+^ or OT-1 *Elf4*^−/−^ mice (CD45.2^+^) were adoptively transferred intravenously into recipient B6.SJL (CD45.1^+^) mice followed by activation with 50 ng of OVA~257--\ 264~ peptide (SIINFEKL) (ANASpec) the following day. CFSE dilution was examined by flow cytometry after 3 days of activation. To evaluate homeostatic proliferation of naïve T cells in lymphopenic hosts, CD8^+^CD44^lo^ T cells (2 × 10^6^) from young CD45.2^+^ *Elf4*^+/+^ or CD45.2^+^ *Elf4*^−/−^ mice were labeled with CFSE and transferred into lymphopenic B6.SJL (CD45.1^+^) mice (irradiated with 4.5 Gy). After 9 days, CFSE dilution was measured in donor-derived cells (CD45.2^+^) in the spleen. For *in vitro* stimulation with OVA~257--264~ peptide, splenocytes from B6.SJL mice were pulsed with different concentrations of OVA~257--264~ peptide at 37°C for 1 h. CFSE-labeled OT-1 CD8^+^ T cells were then stimulated with OVA~257--264~ -pulsed splenocytes. CFSE dilution in CD45.2^+^ cells was analyzed by flow cytometry 3 days later. Percentage of proliferation was calculated respect to the maximum proliferation induced by 1,000 ng/ml OVA~257--264~ peptide.

Immunization with peptide-pulsed DCs {#S15}
------------------------------------

DCs were generated from BM cells cultured with 10 ng/ml of mGM-CSF (Peprotech Inc.). Media was hemi-replenished every 2 days and non-adherent cells were transferred to a new plate at day 6. DCs were activated with 100 ng/ml of LPS (Sigma) for 18 hours and activation (CD11c^+^ CD11b^+^ MHC-class II^hi^ phenotype) was confirmed by flow cytometry. Finally, DCs were pulsed with 5 µg/ml of OVA~257--264~ peptide at 37°C for 1 hour and washed twice with PBS. CD8^+^ T cells were purified from OT-1 *Elf4*^+/+^ and OT-1 *Elf4*^−/−^ mice and adoptively transferred into B6.SJL mice (1 × 10^5^ cells/mouse). Twenty-four hours later, mice were immunized with 1 × 10^6^ peptide-pulsed DCs. Expansion of CD8^+^ T cells in spleen was monitored at different times following immunization by flow cytometry using anti-CD8-APC, anti-CD45.2-FITC and PE-labeled H2-K^b^-OVA tetramer.

*In vivo* cytotoxicity assay {#S16}
----------------------------

The *in vivo* killing assay was performed as previously described [@R52]. Briefly, splenocytes were labeled with two concentrations of CFSE (2 µM or 8 µM) to generate dim and bright populations. To generate target cells, CFSE-bright cells were pulsed with 5 µg/ml of OVA peptide for 1 h at 37 °C and washed twice with 10-fold PBS. The CFSE-dim population was not pulsed with OVA peptide. A mixture of CFSE-dim cells (5 × 10^6^) and CFSE-bright cells (5 × 10^6^) was injected intravenously into mice that were immunized with OVA peptide-pulsed DCs 40 days earlier. CFSE profiles were analyzed in spleen 16 hours after transfer. Specific lysis was calculated by the following formula: Specific lysis = \[(% of CFSE^bright^ - % of CFSE^dim^)/ % of CFSE^dim^×100\].

Isolation of lymphocytes from liver and lung {#S17}
--------------------------------------------

Livers and lungs were perfused after dissection by injecting 5--10 ml of ice-cold PBS into the hepatic artery or into the ventricle of lung, respectively. Both tissues were homogenized using a pestle motor mixer (VWR) in PBS. After washing with PBS, homogenized tissues were incubated in RPMI containing 5% FBS, 0.5 mg/ml of collagenase IV (Sigma-Aldrich) and 1.5 U/ml of DNase I (Qiagen) at 37 °C for 45--60 min. Then, digested tissues were applied to a Ficoll type 40 (Sigma-Aldrich) and centrifuged at 1,900 r.p.m. at 20 °C for 20 min. Lymphocytes were harvested from the interface.

BM transplantation {#S18}
------------------

Bone marrow cells were extracted from femurs and tibias and placed in DMEM (Lonza) with 2% FBS. Cell suspension was filtered through 40-micron cell strainers (BD Falcon). Five million BM cells were injected intravenously into the lateral tail vein of recipient mice that were previously irradiated (4.5 Gy).

Immunoblot {#S19}
----------

CD8^+^ T cells were lysed directly with LDS sample buffer (Invitrogen) at 1 × 10^4^ cells /µl and sonicated to shear DNA. 10 µl of cell lysates were loaded onto NuPAGE Bis-Tris gels (Invitrogen) and proteins were transferred to PVDF membrane. Specific proteins were detected using rabbit polyclonal anti-KLF2 (Aviva Systems Biology) and anti-actin (Sigma-Aldrich). For the analysis of cell cycle regulators, rabbit polyclonal anti-cyclin E, anti-cyclin A, and anti-p21 were purchased from eBioscience. Rabbit polyclonal anti-p27 and mouse anti-cyclin D1, anti-cyclin D3, and anti-cdk4 were purchased from Cell Signaling Technology. To analyze phosphorylation of Rb protein, CD8^+^ T cells were activated in anti-CD3 coated plates with soluble anti-CD28 and lysates were analyzed using rabbit polyclonal anti-phospho-Rb (Cell Signaling Technology). Goat anti-rabbit IgG and goat anti-mouse IgG conjugated with peroxidase (Pierce) were used as secondary antibodies. X-ray films were developed using immunoblotting detection reagent (Westdura).

Quantitative real-time PCR {#S20}
--------------------------

Total RNA was extracted from CD8^+^ T cells by RNeasy Mini kit (Qiagen). Then cDNA was syntyhesized from 100--500 ng RNA with random hexamer primers using SuperScript III kit (Invitrogen). Quantitative real time PCR was performed using LightCycler FastStart DNA Master SYBR Green I (Roche) as specified by the manufacturer. Primer sequences for PCR were as follows: β-*actin* forward (5'-GTGGGCCGCTCTAGGCACCA-3') and reverse (5'-CGGTTGGCCTTAGGGTTCAGGGG-3'), *Elf4* forward (5'-CGGAAGTGCTTTCAGACTCC-3') and reverse (5'-GGTCAGTGACAGGTGAGGTA-3'), *CD62L* forward (5'-CATTCCTGTAGCCGTCATGG-3') and reverse (5'-AGGAGGAGCTGTTGGTCATG-3'), *Klf2* forward (5'-CCAACTGCGGCAAGACCTAC-3') and reverse (5'-AGTCGACCCAGGCTACATGTG-3'), *Klf4* forward (5'-CTGAACAGCAGGGACTGTCA-3') and reverse (5'-GTGTGGGTGGCTGTTCTTTT-3'), *p21* forward (5'-CTGTCTTGCACTCTGGTGTCTGAG-3') and reverse (5'-TTTCTCTTGCAGAAGACCAATCTG-3'). Reactions were run on a Smart Cycler (Cepheid). Thermocycler conditions consisted of an initial step at 95 °C for 10 min, followed by 35 cycles of a 3-step PCR program consisting of 95° C for 15 sec, 55 °C for 30 sec and 72 °C for 30 sec. Relative expression was calculated by normalizing with β-actin expression.

Chromatin Immunoprecipitation {#S21}
-----------------------------

To examine DNA binding of ELF4 or KLF2 protein, ChIP assay was performed using the magnetic chromatin immunoprecipitation kit, ChIP-IT express (Active Motif). Fixed and sheared DNA from wild type and *Elf4*^−/−^ CD8^+^ T cells was prepared and ELF4 or KLF2 was immunoprecipitated. Immunoprecipitated chromatin was amplified by PCR using primers spanning the *Sell (*CD62L*), Klf2* or *Klf4* promoters. Primer sequences for PCR were as follows: *Sell* promoter forward (5'-CTCTCCCTTTCCTTTCCTCCTTCC-3') and reverse (5'-CTCTCCCCACCCCTTTCC-3'), *Klf2* promoter forward (5'-AGTTCGCCAATGTTTCTGCT-3') and reverse (5'-GCATTGAAGCTGTGACCTGA-3'), *Klf4* promoter forward (5'-CCCACTTCATTGGGAAGAGA-3') and reverse (5'-GGACTGAAGAAAGGCACTCG-3'). Thermocycler conditions consisted of an initial step at 94 °C for 10 min, followed by 32 cycles of a 3-step PCR program consisting of 94 °C for 20 sec, 59 °C for 30 sec and 72 °C for 30 sec.

Promoter assay {#S22}
--------------

*Elf4, Mef2c* and *Sp1* cDNAs were cloned into the expression vector pcDNA 3.1/V5-His A (Invitrogen). *Klf2* and *Klf4* promoter regions were cloned from mouse genomic DNA into pGL3-Basic vector (Promega). pGL3-*Klf2* consists of 1.8 kb containing 43 bp of the 5' non-coding region and pGL3-*Klf4* consists of 2.1 kb containing 542 bp of the 5' non-coding region. COS-7 cells were transfected with a mixture of expression vector (200ng), promoter plasmid (20ng) and 4ng of renilla luciferase expression plasmid (pRL-CMV, Promega) using Lipofectamine 2000 (Invitrogen). After 48 hours, all transfectants were analyzed by dual-luciferase reporter assay system (Promega) with luminometer (Sirius, Berthold). Transfection efficiency was normalized with renilla luciferase. The expression of exogeneous ELF4, SP1 and MEF2C was confirmed by immunoblot.

Induction of *Klf4* deletion {#S23}
----------------------------

*Klf4^fl/fl^* Mx1-Cre^+^ mice (2--5 week old) were injected i.p. with poly I:C (300 µg every other day for a total of five times) as described [@R53]. Gene deletion was confirmed by PCR using genomic DNA from CD8^+^ T cells and three primers: *Klf4* exon1, CTGGGCCCCCACATTAATGAG; *Klf4* exon2, CGCTGACAGCCATGTCAGACT; *Klf4* intron3, CAGAGCCGTTCTGGCTGTTTT as described [@R51].

Immunocytochemistry {#S24}
-------------------

Naïve CD8^+^ T cells from mice were spun down onto glass slides, fixed with 1% paraformaldehyde and permeabilized with 0.1% Triton X-100. Slides were stained with cyclin D1-or cyclin D3-specific antibodies and mouse-specific antibody conjugated with Alexa-594. Nuclei were stained with DAPI.

BrdU incorporation {#S25}
------------------

BrdU (2mg) was intraperitonealy injected into 2-month-old *Elf4*^+/+^ and *Elf4*^−/−^ mice every other day for a total 8 times. Splenocytes were stained with anti-CD8-PE, anti-CD44-PerCP-Cy5.5. Then, BrdU incorporation was measured by flow cytometry using the APC BrdU flow kit (BD).

Microarray analysis {#S26}
-------------------

Total RNA was extracted from CD8^+^ T cells purified from *Elf4*^+/+^ and *Elf4*^−/−^ mice using RNeasy Mini kit (QIAGEN). RNA probes were used to hybridize Affymetrix gene chips (mouse 430 version 2.0) in the Microarray Core Facility at Baylor College of Medicine. Data was analyzed using Bioconductor to compare mRNA expression level.
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![ELF4 negatively regulates the proliferation of naïve CD8^+^ T cells\
(**a**) *Elf4*^+/+^ and *Elf4*^−/−^ mice were injected intraperitoneally with bromodeoxyuridine (BrdU). BrdU incorporation by indicated CD8^+^ T cell subsets was analyzed by flow cytometry (*n*=4, \*\* *P* \< 0.01). A representative experiment is shown with four mice per group (mean and s.d.). (**b**) Proliferation of CFSE-labeled naïve *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells was assessed 9 days after adoptive transfer into irradiated B6.SJL mice. The percentage of divided cells and the proliferation indices (PI) are indicated. Data are representative of three independent experiments. (**c**) Proliferation of CFSE-labeled *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^CD44^hi^ and CD8^+^CD44^lo^ T cells stimulated with IL-15 *in vitro* for 7 days was measured by flow cytometry. Data are representative of at least three independent experiments. (**d**) OT-1 *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells were labeled with CFSE and adoptively transferred into B6.SJL mice. One day later, recipient mice were injected with OVA~257--264~ peptide. Three days after OVA~257--264~ injection, CFSE dilution was assessed by flow cytometry. Data are representative of three independent experiments. (**e**) OT-1 *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells were labeled with CFSE and incubated with B6.SJL splenocytes pulsed with the indicated concentrations of OVA~257--264~ peptide. CFSE dilution was measured by flow cytometry. Data are representative of two experiments. (**f**) *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells were stimulated with anti-CD3 and anti-CD28 for the indicated time periods. Rb phosphorylation was assessed by immunoblot. β-actin, loading control. Data are representative of two experiments. (**g**) Expression of the indicated cyclins and CDK inhibitors in unstimulated *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells was measured by immunoblot. Data are representative of two experiments. (**h**) Expression of cyclin D1 and cyclin D3 (magenta) in *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells was assessed by immunofluorescence. DAPI (blue) staining marks the nuclei. Data are representative of two experiments.](nihms105082f1){#F1}

![ELF4 restricts the homeostatic expansion of CD8^+^ T cell populations with a memory-like phenotype\
(**a**) The percentage of CD44^hi^CD122^+^ cells within the CD8^+^ T cell pool in *Elf4*^+/+^ and *Elf4*^−/−^ spleens from mice of different ages (left) was determined by flow cytometry. The proportion and number of CD8^+^CD44^hi^ T cells in the spleen is shown on the right (at least 3 mice were analyzed for each time point). A two-tailed Student's t-test was used to compare *Elf4*^+/+^ and *Elf4*^−/−^ mice (\* *P* \< 0.05, \*\* *P* \< 0.01). Data are representative of three independent experiments. (**b**) BM cells from GFP-transgenic *Elf4*^+/+^ or *Elf4*^−/−^ mice were transplanted into irradiated B6 mice. Expansion of the donor-derived CD8^+^CD44^hi^CD122^+^ T cell populations in the spleen was monitored at different times post-transplantation (*n*=3, \*\* *P* \< 0.01). Data are representative of two independent experiments.](nihms105082f2){#F2}

![The gradual expansion of *Elf4*^−/−^ CD8^+^CD44^hi^ T cell populations leads to reduced CD62L expression\
(**a**) Distribution of CD8^+^CD44^hi^CD122^+^ T cells in lymphoid and non-lymphoid tissues of 13-month-old *Elf4*^+/+^ and *Elf4*^−/−^ mice (mLN, mesenteric lymph node). Data are representative of two experiments. (**b**) Cell surface expression of CD62L on naïve (CD8^+^CD44^lo^) and memory-like (CD8^+^CD44^hi^) T cells from 3 and 13-month-old mice (54±2% CD62L^+^ in *Elf4*^+/+^ T cells versus 24±3% in *Elf4*^−/−^ T cells, *P* \< 0.01, *n*=4). Data are representative of five independent experiments. (**c**) The lineage relationship between memory T cell subsets was examined following adoptive transfer of *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^CD44^hi^CD62L^+^ and CD8^+^CD44^hi^CD62L^−^ cells into B6.SJL (CD45.1^+^) mice. CD62L expression in CD45.2^+^ donor-derived cells was analyzed after 35 days. Data are representative of at least two independent experiments.](nihms105082f3){#F3}

![ELF4 regulates KLF2 and CD62L expression solely in CD8^+^CD44^hi^ T cells from aged mice\
(**a**) KLF2 and CD62L expression relative to β-actin was measured by qPCR (left) and by immunoblot (right, KLF2 only) in CD8^+^ T cells from 3-and 13-month-old *Elf4*^+/+^ and *Elf4*^−/−^ mice. Data are representative of three independent experiments. (**b**) The cell surface expression of CD62L was measured in CD8^+^ T cells from 13-month-old *Elf4*^+/+^ and *Elf4*^−/−^ mice, and from *Elf4*^−/−^ mice expressing a Vav-ELF4 transgene (Tg) by flow cytometry. The sorting gates of CD44^lo^ and CD44^hi^ CD8^+^ T cells used for the next experiment are indicated. Data are representative of two independent experiments in triplicates. (**c**) CD62L and KLF2 expression in purified CD8^+^CD44^lo^ and CD8^+^CD44^hi^ cells from 13-month-old *Elf4*^+/+^, *Elf4*^−/−^, and *Elf4*^−/−^ Tg mice was measured using qPCR. Expression relative to β-actin is shown. Data are representative of two experiments in triplicates (mean and s.d.). (**d**) Promoter occupancy in the *Klf2* (left) and *Sell* (right) regulatory sequences. Sheared DNA from *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells isolated from 13-month-old mice was immunoprecipitated with anti-ELF4 and anti-KLF2 antibodies. The input DNA and immunoprecipitation with IgG control are also shown. Data are representative of at least three independent experiments.](nihms105082f4){#F4}

![*Elf4*^−/−^ CD8^+^ T cells generate more effector and memory T cells following immunization\
(**a**) Purified CD8^+^ T cells from OT-1 *Elf4*^+/+^ or *Elf4*^−/−^ mice (CD45.2^+^) were transferred into B6.SJL mice (CD45.1^+^) and activated 24 h later with DCs pulsed with OVA~257--264~ peptide. The percent and number of donor-derived tetramer-positive cells 4 and 40 days after immunization is shown in the dot plots and bar graphs. The kinetics of OT-1 CD8^+^ T cell population expansion and contraction are also shown. Data are representative of at least three independent experiments. (**b**) CD8^+^ T cells from *Elf4*^+/+^ (CD45.1^+^CD45.2^+^) and *Elf4*^−/−^ (CD45.1^−^ CD45.2^+^) mice were co-transferred into B6.SJL mice (CD45.1^+^CD45.2^−^). One day later, recipient mice were injected with OVA~257--264~ -pulsed DCs and donor CD8^+^ T cells were examined at day 4 (*n*=5, \*\* *P* \< 0.01). Data are representative of two experiments. (**c**) The number of effectors (KLRG1^hi^ IL-7Rα^lo^) and memory precursor cells (KLRG1^lo^ IL-7Rα^hi^) in mice adoptively transferred with OT-1 *Elf4*^+/+^ or OT-1 *Elf4*^−/−^ CD8^+^ T cells was determined by flow cytometry at day 4 after immunization with OVA-pulsed DCs (*n*=3, \*\* *P* \< 0.01). Data are representative of two experiments. (**d**) OT-1 *Elf4*^+/+^ or *Elf4*^−/−^ mice were immunized or not (Control) 40 days prior to injection with a 1:1 mixture of CFSE^dim^-labeled control cells and CFSE^bright^-labeled target cells. The specific lysis was calculated on the basis of flow cytometric enumeration of the CFSE^dim^ and CFSE^bright^ cells in the spleen (*n*=4, \*\* *P* \< 0.01). Data are representative of two independent experiments.](nihms105082f5){#F5}

![ELF4 inhibits T cell proliferation by activating the tumor suppressor KLF4 downstream of TCR signaling\
(**a**) Heat map of the 10 most downregulated genes comparing duplicates of naïve and activated CD8^+^ T cells from *Elf4*^+/+^ and *Elf4*^−/−^ mice by microarray analysis (top). KLF4 expression in naïve CD8^+^ T cells was confirmed by immunoblot (bottom). (**b**) Expression of ELF4, KLF2, and KLF4 mRNA (top) and protein (bottom) at indicated times after TCR activation. mRNA was measured by qPCR and protein was measured by immunoblot. Data are representative of three independent experiments.](nihms105082f6){#F6}

![KLF4, a direct target of ELF4, negatively regulates the proliferation of naïve CD8^+^ T cells\
(**a**) CD8^+^ T cells were isolated from *Elf4*^+/+^, *Elf4*^−/−^, Vav-ELF4 transgenic (Tg), and *Elf4*^−/−^ Tg mice. KLF4 and p21 transcripts were measured by real-time PCR and expressed as relative expression to β-actin. Data are representative of at least two experiments in triplicates (mean and s.d.). (**b**) CD8^+^ T cells from (**a**) were labeled with CFSE and stimulated with anti-CD3 and anti-CD28 *in vitro* for 3 days. CFSE dilution was measured by flow cytometry. The percentage of non-proliferative T cells is indicated. Data are representative of two experiments. (**c**) COS-7 cells expressing a luciferase construct driven by the *Klf4* promoter were transfected with empty vector (Control) or with vectors encoding SP1 or ELF4 proteins. Data are representative of two independent experiments. (**d**) Sheared DNA from *Elf4*^+/+^ and *Elf4*^−/−^ CD8^+^ T cells was immunoprecipitated with an ELF4-specific antibody or an immunoglobulin (IgG) control, and DNA was amplified with primers spanning the *Klf4* proximal promoter. Input, total DNA without immunoprecipitation. Results are representative of three experiments. (**e**) *Klf4*^fl/fl^ Cre^+^ and *Klf4*^fl/fl^ Cre^−^ mice were injected with polyI:C to induce gene deletion. Deletion was confirmed by PCR of genomic DNA isolated from CD8^+^ T cells after 9 months of treatment. CD8^+^CD44^lo^ T cells from these mice were labeled with CFSE and stimulated *in vitro* with anti-CD3 and anti-CD28 for 3 days. CFSE dilution was measured by flow cytometry. (**f**) Thirteen months after polyI:C-induced *Klf4* gene deletion, expression of CD44 and CD122 on splenic CD8^+^ T cells was measured by flow cytometry (*n*=6, \*\**P* \< 0.01). Data are representative of at least three independent experiments.](nihms105082f7){#F7}
